Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Immune Thrombocytopenia Purpura (ITP) is an acquired, immune-mediated disorder characterized by a severe decrease in peripheral thrombocyte count to less than 100 x 10⁹/L, leading to mucocutaneous bleeding. Our primary objective is to evaluate the efficacy of adding Mycophenolate Mofetil (MMF) alongside steroids in the first-line treatment of ITP, aiming for an enhanced therapeutic response, lower risk of refractory and chronic ITP, reduced financial burden, and improved overall outcomes.
The study aims to validate the efficacy and safety of MMF as a first-line treatment option for ITP while reducing the economic burden and risk of relapse associated with the condition
Age
5–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Inclusion Requirements:
Age: 5-60 years • Number of plates: \<30x109
Exclusion Standards:
Pregnancy; lactation; hepatitis B and C; HIV-reactive individuals; and medication allergies